Numerous pathological processes have been linked to disorders of the central 5-hydroxytryptamine (5HT) system but the possibility of gene therapy through modulation of 5HT system remained unexplored due to the lack of the specific targeting vectors. We explored the sequences upstream of the tryptophan hydroxylase-2 (TPH-2) gene, the key enzyme in neuronal 5HT synthesis and generated lentiviral vectors, which were then tested in vivo using microinjections into the rat raphe. All fragments longer than 1 kb (called 2TPH, 3.6TPH and 6.7TPH) drove highly specific expression in 5HT neurons which was, however too weak to be detectable without immunostaining. To enhance the level of expression, a two-step transcriptional amplification strategy was employed whereby the activity of a TPH-2 promoter fragment was potentiated by a chimeric enhancer GAL4|p65. Surprisingly, previously published implementations of this strategy compromised the specificity of expression. We therefore used a new approach where both, the transgene and GAL4|p65 are co-expressed using an internal ribosomal entry site and GAL4|p65 operates in a positive feedback manner to amplify the expression. Thus, we have generated new vectors, which are both, highly specific for 5HT neurons and sufficiently powerful. They open a range of new opportunities for enquiries into genetic correction of 5HT-related disorders.
Introduction
Serotonin (5HT) is an important neurotransmitter, which influences a wide variety of brain functions. [1] [2] [3] [4] [5] Dysfunction of the 5HT system has been implicated in a number of prevalent disorders such as depression and anxiety, 5, 6 drug addiction, 7 obsessive compulsive disorder or schizophrenia. 8, 9 Blockers of 5HT uptake are widely used in clinics, mainly for the treatment of depression, but, overall, progress in development of new therapies for disorders which involve central 5HT transmission has been slow, justifying research into possible use of genetic tools. It is generally agreed that targeted expression of genes to selective cellular phenotypes has advantages for directed modulation of brain function where numerous cell types with different and even opposing functions are typically located close to each other. A method for selective gene expression and manipulation in 5HT neurons would be extremely useful for furthering our understanding of the mechanisms by which 5HT exerts its actions and for enquiries into possibilities for genetic correction of 5HT-related disorders.
A number of viral vectors for targeting specific cellular populations in the brain have been reported over the last few years by ourselves and others. [10] [11] [12] [13] For successful targeting of 5HT neurons with viral vectors, two problems had to be overcome. First, it was necessary to find a promoter, which would be sufficiently selective but also adequately short to be packaged into conventional vectors, such as self-inactivating lentiviral vectors (LVV). We decided to explore the sequences upstream of the tryptophan hydroxylase-2 (TPH-2) gene, the key enzyme in central neuronal 5HT synthesis. 14 Secondly, the promoter had to be sufficiently strong to build up an adequately high concentration of the transgene. In general, mammalian cell-specific promoters (CSP) tend to be relatively weak as compared to those derived from viral pathogens. Here, we relied on the previously successful two-step transcriptional amplification (TSTA) strategy. [15] [16] [17] This strategy is based on a simultaneous cell-specific expression of artificial transcriptional enhancers that operate through unique binding domains placed upstream of a weak promoter. 15, [17] [18] [19] [20] We reasoned that if we could identify a sufficiently specific promoter sequence within the TPH-2 gene, we should be able to amplify its potency using TSTA. Here, we present LVV which selectively and powerfully drive the expression of EGFP in raphe 5HT neurons in vivo.
Results

Selection of the lead promoter sequence
Almost invariably in cell type-selective gene targeting, a set of putative promoter fragments are initially screened on an array of cell lines, which mimic the desired phenotype. However, for targeting 5HT neurons we could not rely on cell lines because, to the best of our knowledge, there is no rodent cell line of brain origin, which has any degree of specificity in terms of 5HT synthesis or transcriptional control. We therefore successfully adopted a different, more direct approach. In vitro we confirmed that the constructs were transcriptionally active and then immediately placed them in LVV and tested in vivo. This approach proved to be successful.
To determine the shortest cell-selective region of the TPH-2 promoter, serially truncated 5 0 -flanking sequences of the TPH-2 gene were PCR amplified from rat brain genomic DNA. Fragments of 1, 2, 3.6 and 6.7 kb length relative to the transcription start site (1TPH, 2TPH, 3.6TPH, 6.7TPH, correspondingly) were subcloned into LVV shuttle plasmids to drive EGFP expression (Table 1 , Supplementary Figure 1) . The resulting plasmids were first tested by transient transfection of IMR32 and PC12 cells and EGFP expression was confirmed in both cell lines (data not shown). In the brain, 5HT neurons are distributed throughout the brainstem and mainly concentrated within two clusters: a caudal group of the midline raphe nuclei, and a more rostral group that includes the dorsal and median raphe nuclei. 21, 22 LVV constructed from the four plasmids were microinjected into the midline raphe nuclei of mature rats and the expression pattern of EGFP was examined. In no case could we detect EGFP in unstained sections. After double immunostaining with anti-GFP and anti-TPH antibodies (Supplementary information), EGFP-positive cells were evident in all LVV-transduced sections (Figure 1a) . In most cases EGFP and TPH immunofluorescence was co-localized, although the degree of co-localization differed between vectors (Figure 1b) . 6.7TPH, 3.6TPH and 2TPH promoter fragments conferred almost complete specificity to 5HT neurons (498%; n4500 cells in each case), whereas 1TPH resulted in only 78% co-localization. It also appeared to be the least active in this group of constructs (Supplementary Table 1 ). Thus, by increasing the TPH-2 promoter length from 1 to 2 kb or more, we were able to turn leaky EGFP expression into a highly 5HT neuron-specific pattern. This suggests the presence of essential control sequences between 1 and 2 kb upstream of the TPH transcription initiation site. The synapsin-1 (SYN) promoter, which was used for comparison purposes, drove expression predominantly in non-TPHpositive neurons (Figure 1 ).
Enhancement of TPH-2 promoter potency
TSTA was used to amplify the expression. The conventional TSTA design (Figure 2a ) requires two expression cassettes both driven by the same CSP. One copy of the promoter expresses the transgene, whereas the other copy expresses a chimeric transcriptional enhancer. As in our previous work 17, 19, 20 we used for this purpose a potent chimeric transactivator consisting of a GAL4-binding domain fused to a part of the transcriptional activation domain of NF-kBp65, one of the strongest known mammalian transcriptional activators. Expression of this enhancer is driven by the first copy of CSP. The transgene cassette contains multimerized GAL4-binding sequences (G4BS) upstream of the second CSP copy and drives the expression of the actual gene of interest, for example EGFP. As GAL4 and its binding site are exclusive to yeast, only the chimeric transactivator GAL4|p65 binds and potentiates transgene expression, and leak expression is minimized. 17 Very recently we have also successfully tested a variation of this approach based on bi-directional transgene expression driven by modified CSPs 20, 23 ( Figure 2b ).
Owing to the size of 3.6TPH in relation to the viral vector capacity, initially we decided to use the conventional two -promoter copy strategy (Figures 2a and d ), but incorporated into two separate LVV. LVV-3.6TPH-GAL4|p65 was designed for an expression of the chimeric artificial enhancer, and LVV-G4BS-3.6TPH-EGFP contained enhancer-binding sites for potentiated transgene expression. Both LVV were mixed at a 1:1 ratio and tested in vivo as described above. Visible EGFP fluorescence could now be detected without immunostaining in the raphe nuclei ( Figure 3a ). More importantly, the vectors were still highly selective for 5HT neurons (99%; n ¼ 700). However, for practical purposes, a singlevector system is often preferable. Using 2TPH as a backbone, we took three different TSTA approaches (Figures 2a-c) . Although the conventional and bi-directional strategies illustrated in Figures 2a and b have been utilized before, 17, 20 the IRES-based strategy illustrated in Figure 2c is introduced here for the first time. Instead of two promoter copies or a bi-directional promoter, only one CSP copy is used to drive the expression of both, the transgene and the transcriptional activator GAL4p65, which are linked through an internal ribosome entry site (IRES). LVV-G4BS-2TPH-EGFP-IRES-GAL4|p65 proved to be potent enough to deliver visible EGFP expression whereas maintaining specificity at 97% (n ¼ 900; Figures 2c and 3a and b). Interestingly, judging from the density of fluorescent 5HT cells, it was also perhaps the most active construct (Supplementary Table 1 indicates that the sequences located in the 5 0 part of 2TPH sequence may be sensitive to influences from adjacent elements, which appear to perturb the specificity of expression.
Discussion
The ability to selectively manipulate gene expression in a chosen type of cell within the otherwise exceedingly Total number of cells is also shown. Note that 2TPH, 3.6TPH and 6.7TPH conferred high 5HT neuron selectivity whereas 1TPH was less specific. SYN-driven EGFP expression was predominantly observed in TPH-negative neurons.
Lentiviral vectors for targeting serotonergic neurons K Benzekhroufa et al heterogeneous tissue of the brain is highly attractive. It is reasonable to expect that this approach should lead to more specific therapeutic actions with fewer side effects. Raphe nuclei, often referred to as serotonergic, comprise a variety of neurochemical phenotypes. For example both, dorsal and medial raphe nuclei give rise to a glutamatergic projection towards the hippocampal formation 24 and glutamatergic neurons are intermingled with the TPH-positive cells which send their axons towards the same targets. Selective genetic manipulation of these parallel connections is impossible without cell-selective vectors such as described here. It is worth noting that a generic 'neuronal' promoter such as SYN is not suitable for targeting 5HT neurons as the majority of the cells which expressed EGFP in animals injected with LVV-SYN-EGFP were non-TPH-positive (Figure 1) . Although in vivo our LVV microinjections were targeted mainly into the midline raphe we have also seen transduced 5HT cells of various other groups (B1, B1/ 3) due to the spread of the virus in the brain parenchyma.
Conventional viral vectors cannot incorporate very large transcriptional control units such as present in 
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bacterial artificial chromosomes and therefore rely on short sequences, which need to be sufficiently specific. Here, we used the sequences found upstream of the first exon of TPH-2, an enzyme expressed only in central 5HT neurons. 14 TPH-2 gene has recently attracted a lot of interest because of the possible causative role of the polymorphisms in it for human psychiatric disorders. 25, 26 Of the several tested fragments of the rat TPH-2, 3.6TPH and 2TPH sequences were approximately equally selective whereas some important control elements were obviously lost in 1TPH. 1TPH promoter also exhibited a lower overall activity (Supplementary Table 1) . Recently it has been demonstrated that 4 kb fragment of the human TPH-2 promoter is more active in cultured embryonic raphe cells as compared to a 1 kb fragment, 26 consistent with our observations. The regulatory importance of the region in the vicinity of À2 kb is also indirectly supported by the fact that when mCMV was cloned directly next to the 5 0 end of 2TPH, specificity was affected. Future research will establish the exact location of enhancers in the TPH-2 promoter, which possibly can be added to 2TPH constructs to further amplify its transcriptional activity. The native TPH-2 promoter sequences, although very selective, were insufficiently Note that both, the 3.6TPH conventional and the 2TPH IRES-based system maintained virtually complete specificity of expression (B99%) whereas the other designs were less 5HT-selective. For specificity assessment sections were immunostained for EGFP (as described above) to also take into account neurons with low level of expression.
Lentiviral vectors for targeting serotonergic neurons K Benzekhroufa et al powerful and we have managed to preserve the specificity in TSTA-enhanced constructs. Using TSTA we were able to achieve visible, although moderate, EGFP fluorescence, comparable to the strength of SYN or neuron-specific enolase promoters. Many of the previous reports where transcriptional amplification was used utilized a fusion of a viral VP16 protein with GAL4 binding domain. 16, 18, 27 In our previous studies we successfully used a mammalian transactivation domain p65. At this point it is unclear whether each of the two chimera has any particular advantage in terms of degree of enhancement or potential side effects or longevity of gene expression. Interestingly only the new design of TSTA where the chimeric enhancer is expressed from the same transcript with EGFP using IRES (Figure 2c ) was successful (Figure 3 ). This design simplifies TSTA and is much more compact than the original one (Figure 2a) . This is important because more space is available for the transgenes of interest. Possibly this design may be generally applied to enhance expression within the context of viral vectors, especially considering adeno-associated virus vectors. We have confirmed that this strategy is effective with at least two other cell-specific promoters (not shown).
Based on earlier estimates of the concentration of EGFP in transduced cells when recombinant EGFP served as a reference, 28 we believe that the brightest fluorescent 5HT neurons targeted with the current constructs expressed B1 mM of EGFP. If a functional transgene other than EGFP were to be expressed in 5HT neurons at this concentration, this should be sufficient to achieve a physiologically significant effect, because most cellular proteins are expressed at much lower levels.
Numerous avenues are now open for further inquiries into the pathophysiology of central 5HT neurons and for development of tools for correction of 5HT-dependent disorders. Given that clinically useful therapeutic effects can be achieved using drugs which are thought to increase 5HT signaling in specific parts of the brain, one avenue to explore would be specific expression of genes which should increase release of transmitter from 5HT neurons.
Importantly, critical control sequences in mammalian CSP are usually highly conserved. A previous study demonstrated that a 4 kb fragment of human TPH2 promoter is able to drive expression in cultures of rat embryonic raphe neurons. 26 In fact, most, if not all CSP tested so far in the context of viral vectors seem to work cross-species. For example, the SYN promoter which is commonly used for viral gene expression in rodent studies was originally cloned from human DNA, 12 the human and mouse promoter sequences of the glial fibrillary acidic protein are active and cell-specific in both rats and mice, 20, 29 this list may be continued. Hence, it is not unlikely that the vectors described here could retain their specificity in primates, which are the best possible approximation of human neurophysiology and pathology.
In summary, we present here the first highly selective LVV based on TSTA, which are suitable for gene expression in raphe 5HT neurons in vivo. We expect that these vectors will be a powerful new resource for researchers interested genetic manipulation of central 5HT transmission.
Materials and methods
Construction of TPH-2 promoter containing viral vectors
Lead promoter sequences were PCR amplified from rat brain genomic DNA (BioChain Institute, Hayward, USA) using BD Biosciences Advantage PCR Kit which contains BD TITANIUM Taq DNA Polymerase. PCR primers for TPH promoter segments were designed according to sequence information obtained from NCBI (Gene ID: 317675) to include restriction sites for further cloning ( Table 1 ). The same 3 0 primer was used for 1TPH, 2TPH and 3.6TPH promoters. For 6.7TPH, a 3.1 kb sequence 5 0 of 3.6TPH was amplified and joined to 3.6TPH through the NheI site. These lead promoter sequences were inserted into pTYF-Sw-linker, a lentiviral shuttle plasmid, upstream of EGFP. 30 Conventional (Figure 2a ), bi-directional (Figure 2b ) and IRES-based designs (Figure 2c ) for TSTA were constructed for 2TPH and 3.6TPH promoters within LVV shuttle plasmids.
Cloning strategies Conventional design. To construct pTYF-G4BS-2x2TPH-EGFP, pTYF-2TPH-EGFP was utilized as a backbone. Multimerized GAL4-binding sequences (G4BS) were inserted between NheI and XmaI sites upstream of 2TPH. The sequence containing the recombinant transactivator GAL4|p65 and SV40pA signal was inserted at the (blunted) NheI site. A second copy of 2TPH was inserted at EcoRV upstream of GAL4|p65 (Supplementary Figure 2) .
For the amplification of 3.6TPH-driven EGFP expression, two vectors were constructed. The transgene vector pTYF-G4BS-3.6TPH-EGFP was assembled by inserting G4BS into pTYF-3.6TPH-EGFP between EcoRV and NheI upstream of 3.6TPH. For the enhancer construct pTYF-3.6TPH-GAL4|p65, the EGFP in pTYF-3.6BTPH-EGFP was replaced by GAL4|p65 using SpeI and NotI sites (Figure 2a ).
Bi-directional design. To construct pTYF-G4BS-mCMV|2TPH-GAL4|p65/EGFP, we PCR amplified the 2TPH fragment from pTYF-2TPH-EGFP using MluI and SpeI containing primers. To replace the SYN promoter in pTYF-mCMV/SYN-EGFP from 20 this vector was digested with MluI and SpeI, resulting in three frag ments: SpeI/SV40pA-GAL4|p65-mCMV-G4BS/MluI, MluI/ SYN/SpeI and SpeI/EGFP-WPRE-pTYF/SpeI. Vector backbone and GAL4|p65-containing fragments were then ligated with the 2TPH fragment using three way ligation (Figure 2b ).
IRES-based design. To construct pTYF-G4BS-2TPH-EGFP-IRES-GAL4|p65, initially, IRES2 was PCR amplified from pIRES2-EGFP (Clontech Laboratories Inc., Mountain View, CA, USA) and inserted into pTYF-Swlinker at XmaI (SmaI) and SacII sites 30 to obtain pTYF-Sw-IRES. An NheI/ GAL4|p65-SV40pA/NheI fragment was excised from pTYF-mCMV/SYN-EGFP and inserted into pTYF-Sw-IRES at the SpeI site downstream of IRES. Finally, a G4BS-2TPH-EGFP fragment was extracted from pTYF-G4BS-2TPH-EGFP and inserted into the above vector upstream of IRES (Figure 2c ).
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Pre-screening of the lead promoter sequences in vitro IMR32 and PC12 cell lines were used for preliminary tests only, 31 All further analysis was carried out in vivo by microinjections of LVV into the rat raphe.
In vivo application of viral vectors
All experiments were conducted in accordance with the Animals Scientific Procedures Act 1986. Briefly, adult male Wistar rats were anesthetized with ketamine and medetomidine i.m. and stereotaxically microinjected with LVV suspension (1-5 Â 10^9 TU ml À1 ) into the medulla oblongata. Three 0.5 ml slow microinjections at three locations along the midline were performed to cover some of the midline and ventral raphe. One week later the animals were terminally anesthetized, the brains were removed and processed for immunohistochemistry and confocal imaging. For each vector, at least four rats were screened. For the description of the stereotaxic surgery and immunohistochemical identification of 5HT neurons and co-localization analysis see Supplementary information. Specificity was assessed in each field of view as percentage of cells, where the EGFP and TPH fluorescence was co-localized and therefore n and s.e.m. in all figure legends refers to the number of fields of view screened for each construct. Total number of cells is also given.
For further information about the protocols used for LVV production, surgery and immunohistochemistry, please see Supplementary information.
